• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利：CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法，用中文像聊天一样搜索，搜遍4000万医学文献。AI智能推荐，让科研检索更轻松。

立即免费搜索

文件翻译

保留排版，准确专业，支持PDF/Word/PPT等文件格式，支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述，25分钟生成高质量综述，智能提取关键信息，辅助科研写作。

立即免费体验

相似文献

1
The effect of competing direct-to-consumer advertising campaigns on the use of drugs for benign prostatic hyperplasia: time series analysis.直接面向消费者的竞争性广告活动对良性前列腺增生症药物使用的影响：时间序列分析
J Gen Intern Med. 2015 Apr;30(4):514-20. doi: 10.1007/s11606-014-3063-y. Epub 2014 Oct 23.
2
Efficacy and safety of a fixed-dose combination of dutasteride and tamsulosin treatment (Duodart(®) ) compared with watchful waiting with initiation of tamsulosin therapy if symptoms do not improve, both provided with lifestyle advice, in the management of treatment-naïve men with moderately symptomatic benign prostatic hyperplasia: 2-year CONDUCT study results.度他雄胺与坦索罗辛固定剂量复方制剂（Duodart®）治疗初治的中度症状性良性前列腺增生男性患者的疗效和安全性，与症状未改善时开始坦索罗辛治疗并给予生活方式建议的观察等待策略相比：2年CONDUCT研究结果
BJU Int. 2015 Sep;116(3):450-9. doi: 10.1111/bju.13033. Epub 2015 Jan 29.
3
Clinical outcomes after combined therapy with dutasteride plus tamsulosin or either monotherapy in men with benign prostatic hyperplasia (BPH) by baseline characteristics: 4-year results from the randomized, double-blind Combination of Avodart and Tamsulosin (CombAT) trial.联合治疗比单独治疗对前列腺增生（BPH）患者的临床效果：基线特征的 4 年随机、双盲阿夫唑嗪和坦索罗辛联合治疗（CombAT）试验结果。
BJU Int. 2011 Mar;107(6):946-54. doi: 10.1111/j.1464-410X.2011.10124.x. Epub 2011 Feb 18.
4
Efficacy and safety of dutasteride for the treatment of symptomatic benign prostatic hyperplasia (BPH): a systematic review and meta-analysis.度他雄胺治疗有症状良性前列腺增生（BPH）的疗效和安全性：一项系统评价和荟萃分析。
World J Urol. 2014 Aug;32(4):1093-105. doi: 10.1007/s00345-014-1258-9. Epub 2014 Feb 6.
5
The effects of combination therapy with dutasteride and tamsulosin on clinical outcomes in men with symptomatic benign prostatic hyperplasia: 4-year results from the CombAT study.度他雄胺和坦索罗辛联合治疗对有症状的良性前列腺增生症男性临床结局的影响：来自 CombAT 研究的 4 年结果。
Eur Urol. 2010 Jan;57(1):123-31. doi: 10.1016/j.eururo.2009.09.035. Epub 2009 Sep 19.
6
The influence of baseline parameters on changes in international prostate symptom score with dutasteride, tamsulosin, and combination therapy among men with symptomatic benign prostatic hyperplasia and an enlarged prostate: 2-year data from the CombAT study.基线参数对有症状的良性前列腺增生和前列腺肿大男性使用度他雄胺、坦索罗辛及联合治疗后国际前列腺症状评分变化的影响：CombAT研究的2年数据
Eur Urol. 2009 Feb;55(2):461-71. doi: 10.1016/j.eururo.2008.10.037. Epub 2008 Nov 6.
7
Dutasteride plus tamsulosin fixed-dose combination first-line therapy versus tamsulosin monotherapy in the treatment of benign prostatic hyperplasia: a budget impact analysis in the Greek healthcare setting.度他雄胺与坦索罗辛固定剂量联合用药一线治疗与坦索罗辛单药治疗良性前列腺增生的对比：希腊医疗环境下的预算影响分析
BMC Urol. 2014 Sep 26;14:78. doi: 10.1186/1471-2490-14-78.
8
A 52-week multicenter randomized controlled study of the efficacy and safety of add-on dutasteride and imidafenacin to tamsulosin in patients with benign prostatic hyperplasia with remaining overactive bladder symptoms (DIrecT study).一项为期52周的多中心随机对照研究，评估在伴有残余膀胱过度活动症症状的良性前列腺增生患者中，在坦索罗辛基础上加用度他雄胺和咪达非那新的疗效和安全性（DIRECT研究）
Low Urin Tract Symptoms. 2019 May;11(3):115-121. doi: 10.1111/luts.12243. Epub 2018 Oct 24.
9
Influence of baseline variables on changes in International Prostate Symptom Score after combined therapy with dutasteride plus tamsulosin or either monotherapy in patients with benign prostatic hyperplasia and lower urinary tract symptoms: 4-year results of the CombAT study.度他雄胺联合坦索罗辛或单药治疗良性前列腺增生伴下尿路症状患者后国际前列腺症状评分变化的基线变量影响：CombAT 研究 4 年结果。
BJU Int. 2014 Apr;113(4):623-35. doi: 10.1111/bju.12500. Epub 2014 Jan 9.
10
A prospective randomised placebo-controlled study of the impact of dutasteride/tamsulosin combination therapy on sexual function domains in sexually active men with lower urinary tract symptoms (LUTS) secondary to benign prostatic hyperplasia (BPH).一项多沙唑嗪/坦索罗辛联合治疗对良性前列腺增生（BPH）继发下尿路症状（LUTS）男性性功能领域影响的前瞻性随机安慰剂对照研究。
BJU Int. 2018 Apr;121(4):647-658. doi: 10.1111/bju.14057. Epub 2017 Nov 16.

引用本文的文献

1
Google Search Trends to assess public interest in and concern about Vuity for treating presbyopia.利用谷歌搜索趋势评估公众对治疗老花眼的 Vuity 的兴趣和关注。
PLoS One. 2023 Oct 26;18(10):e0293066. doi: 10.1371/journal.pone.0293066. eCollection 2023.
2
Implications of Public Interest in Colonoscopy: Analysis of Google Trends Data From 12 European Countries.公众对结肠镜检查的关注影响：来自12个欧洲国家的谷歌趋势数据分析
Cureus. 2023 Jul 24;15(7):e42395. doi: 10.7759/cureus.42395. eCollection 2023 Jul.
3
Patient Understanding of Oncology Clinical Trial Endpoints in Direct-to-Consumer Television Advertising.患者对直接面向消费者的电视广告中肿瘤临床试验终点的理解。
Oncologist. 2023 Jul 5;28(7):e542-e553. doi: 10.1093/oncolo/oyad064.
4
Social media and internet search data to inform drug utilization: A systematic scoping review.用于药物利用信息的社交媒体和互联网搜索数据：一项系统性综述。
Front Digit Health. 2023 Mar 20;5:1074961. doi: 10.3389/fdgth.2023.1074961. eCollection 2023.
5
Impact of direct-to-consumer drug advertising during the Super Bowl on drug utilization.超级碗期间直接面向消费者的药品广告对药物使用的影响。
Res Social Adm Pharm. 2020 Aug;16(8):1136-1139. doi: 10.1016/j.sapharm.2019.12.006. Epub 2019 Dec 9.
6
Assessing the Methods, Tools, and Statistical Approaches in Google Trends Research: Systematic Review.评估谷歌趋势研究中的方法、工具和统计方法：系统评价
J Med Internet Res. 2018 Nov 6;20(11):e270. doi: 10.2196/jmir.9366.
7
Trends in Media Reports, Oral Bisphosphonate Prescriptions, and Hip Fractures 1996-2012: An Ecological Analysis.1996 - 2012年媒体报道、口服双膦酸盐处方及髋部骨折的趋势：一项生态分析
J Bone Miner Res. 2015 Dec;30(12):2179-87. doi: 10.1002/jbmr.2565. Epub 2015 Jul 14.
8
Effect of Direct-to-Consumer Advertising on Asthma Medication Sales and Healthcare Use.直接面向消费者的广告对哮喘药物销售和医疗保健使用的影响。
Am J Respir Crit Care Med. 2015 Jul 1;192(1):40-6. doi: 10.1164/rccm.201409-1585OC.
9
A failure to communicate.沟通失败。
J Gen Intern Med. 2015 Apr;30(4):379-80. doi: 10.1007/s11606-015-3203-z.
10
Direct to consumer advertising: the case for greater consumer control.直接面向消费者的广告：加强消费者控制的理由。
J Gen Intern Med. 2015 Apr;30(4):392-4. doi: 10.1007/s11606-015-3187-8.

本文引用的文献

1
Direct-to-consumer television advertising: time to turn off the tube?面向消费者的电视广告：是时候关掉电视了吗？
J Gen Intern Med. 2013 Jul;28(7):862-4. doi: 10.1007/s11606-013-2424-2.
2
Promotion of prescription drugs to consumers and providers, 2001-2010.2001-2010 年向消费者和医疗服务提供者促销处方药情况。
PLoS One. 2013;8(3):e55504. doi: 10.1371/journal.pone.0055504. Epub 2013 Mar 4.
3
Impact of oncology-related direct-to-consumer advertising: association with appropriate and inappropriate prescriptions.肿瘤学相关直接面向消费者广告的影响：与适当和不适当处方的关联。
Cancer. 2013 Mar 1;119(5):1065-72. doi: 10.1002/cncr.27814. Epub 2012 Nov 6.
4
Advertising of prescription-only medicines to the public: does evidence of benefit counterbalance harm?向公众宣传处方药物：获益的证据是否能抵消危害？
Annu Rev Public Health. 2012 Apr;33:259-77. doi: 10.1146/annurev-publhealth-031811-124540.
5
Use of fibrates in the United States and Canada.在美国和加拿大使用贝特类药物。
JAMA. 2011 Mar 23;305(12):1217-24. doi: 10.1001/jama.2011.353.
6
Costs and consequences of direct-to-consumer advertising for clopidogrel in Medicaid.氯吡格雷面向医疗补助计划人群进行直接面向消费者广告宣传的成本与后果。
Arch Intern Med. 2009 Nov 23;169(21):1969-74. doi: 10.1001/archinternmed.2009.320.
7
Direct-to-consumer and physician promotion of tegaserod correlated with physician visits, diagnoses, and prescriptions.面向消费者和医生的替加色罗促销活动与医生问诊、诊断及处方相关。
Gastroenterology. 2009 Aug;137(2):518-24, 524.e1-2. doi: 10.1053/j.gastro.2009.05.005. Epub 2009 May 13.
8
Effect of illicit direct to consumer advertising on use of etanercept, mometasone, and tegaserod in Canada: controlled longitudinal study.非法面向消费者的广告对加拿大依那西普、莫米松和替加色罗使用情况的影响：对照纵向研究
BMJ. 2008 Sep 2;337:a1055. doi: 10.1136/bmj.a1055.
9
Time to ban direct-to-consumer prescription drug marketing.是时候禁止直接面向消费者的处方药营销了。
Ann Fam Med. 2007 Mar-Apr;5(2):101-4. doi: 10.1370/afm.693.
10
Prevalence of lower urinary tract symptoms and effect on quality of life in a racially and ethnically diverse random sample: the Boston Area Community Health (BACH) Survey.不同种族和民族随机样本中下尿路症状的患病率及其对生活质量的影响：波士顿地区社区健康（BACH）调查
Arch Intern Med. 2006 Nov 27;166(21):2381-7. doi: 10.1001/archinte.166.21.2381.

直接面向消费者的竞争性广告活动对良性前列腺增生症药物使用的影响：时间序列分析

The effect of competing direct-to-consumer advertising campaigns on the use of drugs for benign prostatic hyperplasia: time series analysis.

作者信息

Skeldon Sean C, Kozhimannil Katy B, Majumdar Sumit R, Law Michael R

机构信息

The Centre for Health Services and Policy Research, School of Population and Public Health, The University of British Columbia, Vancouver, BC, Canada,

出版信息

J Gen Intern Med. 2015 Apr;30(4):514-20. doi: 10.1007/s11606-014-3063-y. Epub 2014 Oct 23.

DOI:10.1007/s11606-014-3063-y
PMID:25338730
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC4371008/
Abstract

BACKGROUND

Direct-to-consumer advertising (DTCA) remains a controversial issue, with concerns that it leads to unnecessary and inappropriate prescribing. Whether DTCA shifts prescribing from first-line (guideline-recommended) therapy to second-line drugs has not been studied.

OBJECTIVE

The purpose of this study was to determine the impact of sequential DTCA campaigns for two drugs used to treat benign prostatic hyperplasia (BPH): one newer agent, dutasteride (Avodart(®)), and one older first-line agent, tamsulosin (Flomax(®)).

DESIGN

Interrupted time series analysis was used to assess the impact of each DTCA campaign using data on consumer "response" from Google Trends and dispensed prescriptions from IMS Health.

PARTICIPANTS

We analyzed data for the United States from January 2003 to December 2007.

INTERVENTION

DTCA for dutasteride and tamsulosin commenced on July, 2005 and April, 2006, respectively.

MAIN MEASURES

Monthly Internet search volume (scaled from 0 to 100) for the advertised trade name of each drug and monthly U.S. prescription rates per 1,000 population were analyzed.

KEY RESULTS

The dutasteride campaign was associated with an increase in Internet searches for both "Avodart" (level change +31.3 %, 95 % CI: 27.2-35.4) and "Flomax" (level change +8.3 %, 95 % CI: 0.9-15.7), whereas the tamsulosin campaign was associated with increased "Flomax" searches (level change +25.3 %, 95 % CI: 18.7-31.8). The dutasteride campaign was associated with an increase in the prescription of dutasteride (trend = 0.45/month, 95 % CI: 0.33-0.56), but a larger impact was observed with tamsulosin prescriptions (trend = 0.76/month, 95 % CI: 0.02-1.50). Similarly, the tamsulosin campaign was associated with an immediate fourfold increase in the prescribing of tamsulosin (level change +5.76 units, 95 % CI: 1.79-9.72) compared to dutasteride (level change +1.47 units, 95 % CI: 0.79-2.14).

CONCLUSIONS

DTCA was associated with the utilization of drugs to treat symptomatic BPH. However, both campaigns were associated with greater increases in the use of the guideline-recommended first-line agent. DTCA campaigns may increase the overall levels of guideline-recommended treatments to a greater extent than the specific advertised agents.

摘要

背景

直接面向消费者的广告宣传（DTCA）仍是一个有争议的问题，人们担心它会导致不必要和不适当的处方。DTCA是否会使处方从一线（指南推荐）治疗转向二线药物尚未得到研究。

目的

本研究的目的是确定针对两种用于治疗良性前列腺增生（BPH）的药物进行的连续DTCA活动的影响：一种是新型药物度他雄胺（Avodart®），另一种是旧的一线药物坦索罗辛（Flomax®）。

设计

采用中断时间序列分析，利用来自谷歌趋势的消费者“反应”数据和来自艾美仕市场研究公司（IMS Health）的配药处方数据，评估每次DTCA活动的影响。

参与者

我们分析了2003年1月至2007年12月美国的数据。

干预

度他雄胺和坦索罗辛的DTCA分别于2005年7月和2006年4月开始。

主要测量指标

分析了每种药物的广告商品名的每月互联网搜索量（范围从0到100）以及每千人口的每月美国处方率。

主要结果

度他雄胺活动与“Avodart”（水平变化+31.3%，95%可信区间：27.2 - 35.4）和“Flomax”（水平变化+8.3%，95%可信区间：0.9 - 15.7）的互联网搜索量增加有关，而坦索罗辛活动与“Flomax”搜索量增加有关（水平变化+25.3%，95%可信区间：18.7 - 31.8）。度他雄胺活动与度他雄胺处方量增加有关（趋势=0.45/月，95%可信区间：0.33 - 0.56），但坦索罗辛处方量的影响更大（趋势=0.76/月，95%可信区间：0.02 - 1.50）。同样，与度他雄胺（水平变化+1.47单位，95%可信区间：0.79 - 2.14）相比，坦索罗辛活动使坦索罗辛的处方量立即增加了四倍（水平变化+5.76单位，95%可信区间：1.79 - 9.72）。

结论

DTCA与治疗有症状BPH的药物使用有关。然而两个活动都与指南推荐的一线药物使用的更大增加有关。DTCA活动可能在更大程度上提高指南推荐治疗的总体水平，而不是特定广告药物的水平。